This platform provides Research Use Only (RUO) biochemical materials. By proceeding, you confirm and attest the following:
Research Use Only · Not for human consumption · Not FDA evaluated
Triple Agonist GLP3
Triple agonist that activates GLP-1, GIP, and glucagon receptors. Users mainly care about its powerful appetite control and high average weight loss, including reductions in both regular and deep belly fat, while helping preserve muscle better than older weight-loss drugs.
Analytical Profile
Triple Agonist GLP3 is a research peptide that activates the GLP-1, GIP, and glucagon receptors. It is studied primarily for its effects on appetite regulation, energy expenditure, and significant body weight reduction. By stimulating the GLP-1 and GIP pathways, Triple Agonist GLP3 helps reduce food noise and improve satiety, while the glucagon receptor activation is believed to increase energy expenditure and support the breakdown of stored fat, including visceral fat. Research has shown it produces substantial weight loss, often greater than dual or single agonists, making it a compound of high interest for metabolic and obesity-related studies.